Charles Ryan
Professor of Medicine, Division of Hematology, Oncology and Transplantation at University of Minnesota/ Chief Executive Officer at Prostate Cancer Foundation at Harvard Medical School
Biography
Harvard Medical School
Charles J. Ryan, MD, is the President and CEO of the Prostate Cancer Foundation. Dr. Ryan is an internationally recognized genitourinary (GU) oncologist with expertise in the biology and treatment of advanced disease as well as the supportive care of all men with prostate cancer. He was most recently the Director of the Hematology, Oncology and Transplantation Division in the Department of Medicine at the University of Minnesota, Minneapolis. He also served as the Associate Director for Clinical Research in the Masonic Cancer Center and held the B.J. Kennedy Chair in Clinical Medical Oncology.
Dr. Ryan earned a BA in Philosophy, magna cum laude, from Marquette University and graduated from the University of Wisconsin Medical School. He trained at the University of Wisconsin Hospital and Clinics, serving as Chief Resident, and at Memorial Sloan Kettering Cancer Center in New York. Prior to moving to the University of Minnesota, he was on the faculty of the University of California, San Francisco, where he served as Program Leader for Genitourinary Medical Oncology and held the title of Thomas Perkins Distinguished Professor in Cancer Research. He has published over 200 articles and chapters in the world’s leading medical journals. He is the author of the book The Virility Paradox: The Vast Influence of Testosterone on Our Bodies, Minds, and the World We Live In, released in February 2018. Dr. Ryan is also the Leader of the Advanced Prostate Cancer Cadre in the Alliance for Clinical Trials in Oncology, a national clinical trials group, and past Chair of the NCI GU Steering Committee’s Prostate Cancer Task Force.
Dr. Ryan, who goes by the name Chuck, is a native of Appleton, Wisconsin. He has three children with his wife, Jessica: identical twin daughters Cate and Elise, and a son, Patrick.
Videos
Clinical Trials in Non-Metastatic CRPC
Dr. Ryan on Prescribing Preferences in Prostate Cancer and RCC
Dr. Charles Ryan Discusses IMAAGEN Trial Update for Prostate Cancer
Dr. Ryan on Bone-Targeting Agents for Patients With Prostate Cancer
Docetaxel in Metastatic Prostate Cancer
Drs. Charles Ryan and Alicia Morgans talk about: Metastatic Castration-Resistant Prostate Cancer.
Dr. Charles J. Ryan on Patients with mCRPC Treated with Abiraterone
Dr. Charles Ryan Discusses Sequencing Prechemotherapy Castration-Resistant Prostate Cancer Therapies
Expert prostate discussion: Clinical diagnostics, genomics, systemic and radiological treatment
Novel Prostate Cancer Biomarkers
January 8, 2019 - Charles Ryan, MD
Charles Ryan, MD: The Differences in Side Effects Between the Two AR-Targeted Therapies
IMER Thought Leader Conversations - Prostate Cancer: Charles J. Ryan, MD
COU-AA-302: Abiraterone in Pre-Chemo CRPC
Clinical Trial Challenges in Metastatic CRPC
Read about executive education
Other experts
Popular Courses
The Positive Leader: Deep Change and Organizational Transformation
Stephen M. Ross School of Business
Ann Arbor, Michigan, United States
Dec 1
Private Equity: Investing and Creating Value
The Wharton School
Philadelphia, Pennsylvania, United States
Feb 2, 2025
Leading People and Teams
ESMT
Berlin, Germany
Nov 19
Looking for an expert?
Contact us and we'll find the best option for you.